Cells (Apr 2022)

Intranasal Administration of Agomir-let-7i Improves Cognitive Function in Mice with Traumatic Brain Injury

  • Xuan-Cheng He,
  • Jian Wang,
  • Hong-Zhen Du,
  • Chang-Mei Liu,
  • Zhao-Qian Teng

DOI
https://doi.org/10.3390/cells11081348
Journal volume & issue
Vol. 11, no. 8
p. 1348

Abstract

Read online

Overcoming the lack of drugs for the treatment of traumatic brain injury (TBI) has long been a major challenge for the pharmaceutical industry. MiRNAs have emerged as potential targets for progress assessment and intervention against TBI. The brain-enriched miRNA let-7i has been proposed as an ideal candidate biomarker for TBI, but its regulatory roles in brain injury remain largely unknown. Here, we find that the expression of let-7i is significantly downregulated in the early stages of a hippocampal stab wound injury. The noninvasive intranasal administration of let-7i agomir significantly improves cognitive function and suppresses neuroinflammation, glial scar formation, and neuronal apoptosis in TBI mice. Mechanically, STING is a direct downstream target of let-7i after brain injury. Furthermore, the intranasal delivery of let-7i agomir can also effectively inhibit STING and is beneficial for inflammation resolution and neuronal survival in a mouse model of pial vessel disruption stroke. Consequently, let-7i agomir is a promising candidate for clinical application as a chemically engineered oligonucleotides-based therapeutic for brain injury.

Keywords